Study to Compare 2 Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Frown Lines Clinical Trial

— H2H  

Official title:

A Double-Blinded, Randomized, Controlled Study to Compare the Efficacy, Time to Onset, and Duration of Effect of Botulinum Type A Toxins in the Treatment of Glabellar Frown Lines

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT04763265
• Other study ID #: CPH-201-201461
• Status: Completed
• Phase: Phase 2
• Start date: December 18, 2019
• Est. completion date: February 1, 2021

Study information

• Verified date: January 2021
• Source: Croma-Pharma GmbH
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

The purpose of the study is to provide preliminary comparative data on BoNT/A-DP versus Botox Cosmetic. Subsequently the sample size is primarily based on clinical judgement and practical considerations.

Description:

This will be a multi-center, randomized, double-blind, comparator-controlled study. The study will take place in the EU, US and Canada. To allow all subjects to profit from treatment and to obtain adequate data for BoNT/A DP treatment, the study will be comprised of a double-blinded treatment comparing BoNT/A-DP with Botox Cosmetic (ratio 1:1). Primary and secondary endpoints will compare efficacy, safety and subject satisfaction after a single treatment of the investigational BoNT/A DP to an existing commercially available product (Botox Cosmetic). Two hundred subjects will be enrolled, which should allow for a precise estimate of response rate and for post-hoc sensitivity analyses. The duration of study participation for each subject will be up to 18 weeks, to include screening (maximum of 2 weeks; re-screening will not be permitted), and a single treatment (comprised of one injection at five injection points) of BoNT/A-DP (Group A) or Botox Cosmetic (Group B) followed by six efficacy and safety follow-up visits. A total of 200 subjects will be randomized 1:1 to Group A or Group B at Baseline. Both investigators and subjects will be blinded to treatment. Investigators and subjects will evaluate the severity of glabellar lines independently.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 200
• Est. completion date: February 1, 2021
• Est. primary completion date: October 8, 2020
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years to 75 Years

Eligibility

Inclusion Criteria:• Has moderate to severe glabellar frown lines at maximum frown (severity score of 2 or 3 on GLS-I/GLS-S) as determined by in clinic assessments by both the investigator and the subject (where: 0='none', 1='mild', 2='moderate', 3='severe').

• Subject has a stable medical condition with no uncontrolled systemic disease.
• Female subjects of childbearing potential must test negative for pregnancy and agree to use highly effective birth control during the course of the study.
• Subjects who wear glasses must be able to adequately self-assess the severity of their glabellar lines (according to the GLS-S), without glasses obstructing the forehead area.

Exclusion Criteria:

• Previous treatment with any serotype of botulinum toxin for any indication within the 12 months prior to Screening, or any planned treatment with botulinum toxin of any serotype for any reason during the study (other than the investigational treatment).
• Known hypersensitivity to either study medication or its excipients.
• Any medical condition that may place the subject at increased risk due to exposure to botulinum toxin, including diagnosed myasthenia gravis, Eaton-Lambert syndrome, amyotrophic lateral sclerosis, profound atrophy or weakness in the target muscles, or any other condition (at the investigator's discretion) that might interfere with neuromuscular function or contraindicate botulinum toxin therapy.
• Facial laser or light treatment, microdermabrasion, superficial peels or retinoid therapy within the three months prior to Screening or planned during the study. o Apart from the procedures specified above, previous treatment with any facial aesthetic procedure in the glabellar area (including chemical peeling, injection with biodegradable fillers, photo rejuvenation) within 12 months prior to Screening or planned during the study.
• Previous insertion of permanent material in the glabellar area, or planned insertion during the study.
• Any planned or history of surgery in the glabellar area and/or canthal line area, or scars in the glabellar and/or canthal line.
• Active skin disease/infection or irritation at the treatment area.
• Inability to substantially lessen glabellar frown lines and or lateral canthal lines even by physically spreading them apart.
• Use of a muscle relaxant within 2 weeks prior to Screening, or planned use during the study.
• Marked facial asymmetry or ptosis of eyelid and/or eyebrow, or current facial palsy or neuromuscular junction disorders as judged by the investigator.
• Pregnant, breastfeeding or planning to become pregnant during the study.
• Use of prohibited medication including anticholinergic drugs, or drugs which could interfere with neuromuscular function, including aminoglycoside antibiotics and curare-like compounds within 2 weeks prior to Screening or planned during the study.
• Planned surgery with general anesthetic (use of local anesthetic outside the glabellar area is permitted).
• Participation in another clinical study within one month of Screening and throughout the study.
• Previous participation in another botulinum toxin aesthetic study, which involved the treatment of glabellar, lines in combination with canthal lines and/or forehead lines in the previous 18 months.
• Chronic drug or alcohol abuse (as per investigator discretion).

Related Conditions & MeSH terms

• Frown Lines

Intervention

Biological:
• Botulinum toxin A "BoNT/A-DP"
To assess the efficacy of treatment with BoNT/A-DP in reducing the severity of glabellar frown lines at maximum frown.
• Botulinum toxin A "Botox Cosmetics"
To assess the efficacy of treatment with Botox Cosmetics in reducing the severity of glabellar frown lines at maximum frown.

Locations

Country	Name	City	State
Austria	Monika Sulovsky	Vienna
Canada	Institute Of Cosmetic	Oakville	Ontario
Canada	Sweat Clinics of Canada	Toronto	Ontario
United States	Skin Research Institute LLC	Coral Gables	Florida
United States	ATS Clinical Research	Santa Monica	California

Sponsors (2)

Lead Sponsor	Collaborator
Croma-Pharma GmbH	Hugel

Countries where clinical trial is conducted

United States,  Austria,  Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	To provide comparative efficacy data of BoNT/A DP versus Botox Cosmetic by comparing responder rates at week 4 based using the 5-point Facial Wrinkle Scale (FWS; where 0 means no glabellar lines and 4 means extreme glabellar lines).	To assess the efficacy of treatment with BoNT/A-DP as defined by the percentage of responders at Week 4 (Facial Wrinkle Scale [FWS] score of 0 or 1 and a = 1 point reduction in FWS score) in reducing the severity of glabellar frown lines at maximum frown (the worst appearance of upper facial lines with maximum load on the muscle; eyebrows pushed together as far as they can go) compared to treatment with Botox Cosmetic, based on independent investigator assessment and subject assessment.	week 4
Secondary	Responder rates based on FWS Scores of 0 or 1 and a = 1 point reduction in FWS score at maximum frown at weeks 1, 2, 8, 12 and 16	To assess the percentage of responders (FWS score of 0 or 1 and a; = 1 point reduction in FWS score at maximum frown) after a single treatment with BoNT/A-DP compared to a single treatment of Botox Cosmetic at Weeks 1, 2, 8, 12 and 16, based on investigator and subject assessments.	Study weeks 1, 2, 8, 12 and 16
Secondary	Responder rates based on FWS Scores of 0 or 1 and a = 2 point reduction in FWS score at maximum frown at weeks 1, 2, 4, 8, 12 and 16	To assess the percentage of responders (FWS score of 0 or 1 and a; = 2 point reduction in FWS score at maximum frown) after a single treatment with BoNT/A-DP compared to a single treatment of Botox Cosmetic at Weeks 1, 2, 4, 8, 12 and 16, based on independent investigator and subject assessments.	Study weeks 1, 2, 4, 8, 12 and 16
Secondary	To assess treatment satisfaction at Weeks 4, 12, and 16 using FACE-Q Satisfaction with Outcome Scale.	To assess treatment satisfaction at Weeks 4, 12, and 16 using FACE-Q Satisfaction with Outcome Scale.	Study weeks 4, 12 and 16
Secondary	To determine the safety of a single treatment of BoNT/A-DP compared to a single treatment of Botox Cosmetic in the treatment of glabellar lines.	Frequency, seriousness and severity of treatment-emergent adverse events (TEAEs), serious AEs (SAEs) and AEs of special interest (AESIs), as well as causal relationship to the study medication and the study procedure, during the entire study period.	through study completion, an average of 16 weeks